Last reviewed · How we verify
Influenza vaccine GSK1562902A Formulation 2
Influenza vaccine GSK1562902A Formulation 2 is a Inactivated influenza vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Seasonal influenza prevention in adults.
This vaccine stimulates the immune system to recognize and respond to influenza virus antigens, providing protection against seasonal influenza infection.
This vaccine stimulates the immune system to recognize and respond to influenza virus antigens, providing protection against seasonal influenza infection. Used for Seasonal influenza prevention in adults.
At a glance
| Generic name | Influenza vaccine GSK1562902A Formulation 2 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
GSK1562902A Formulation 2 is an inactivated influenza vaccine designed to induce both humoral and cellular immune responses against circulating influenza strains. By presenting viral antigens to the immune system, the vaccine trains B and T cells to recognize and neutralize the virus upon natural exposure, reducing infection risk and disease severity.
Approved indications
- Seasonal influenza prevention in adults
Common side effects
- Injection site pain or erythema
- Myalgia
- Headache
- Fatigue
Key clinical trials
- Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A) (PHASE2)
- Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children (PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children (PHASE3)
- Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above (PHASE3)
- Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Influenza vaccine GSK1562902A Formulation 2 CI brief — competitive landscape report
- Influenza vaccine GSK1562902A Formulation 2 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Influenza vaccine GSK1562902A Formulation 2
What is Influenza vaccine GSK1562902A Formulation 2?
How does Influenza vaccine GSK1562902A Formulation 2 work?
What is Influenza vaccine GSK1562902A Formulation 2 used for?
Who makes Influenza vaccine GSK1562902A Formulation 2?
What drug class is Influenza vaccine GSK1562902A Formulation 2 in?
What development phase is Influenza vaccine GSK1562902A Formulation 2 in?
What are the side effects of Influenza vaccine GSK1562902A Formulation 2?
Related
- Drug class: All Inactivated influenza vaccine drugs
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Seasonal influenza prevention in adults
- Compare: Influenza vaccine GSK1562902A Formulation 2 vs similar drugs
- Pricing: Influenza vaccine GSK1562902A Formulation 2 cost, discount & access